SEngine Precision Medicine
Seattle
About SEngine Precision Medicine
SEngine Precision Medicine uses algorithms and 3D organoid technology to develop drugs with more efficacy. It empowers patients and oncologists with more informed treatment options. The company's technology simultaneously tests more than 200 cancer drugs against a patient's unique tumor organoid outside the body. The results decode the most effective and least toxic treatment options that DNA sequencing alone cannot reveal. Its proprietary platform leverages the aggregated, anonymized test results to develop new cancer-fighting drugs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $21.2M
- Funding stage: Early Stage Venture
- Last round: Series A (Jul 2022)
- Website: senginemedicine.com
- Phone: (833) 736-4163
Industries & Categories
Biotechnology, Health Care, Medical, Precision Medicine
Social Profiles
Canonical: https://fsome.com/organization/sengine-precision-medicine-57154 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.